NCT07082062 Effects of GLP-1 Formula on GLP-1 and Glucose Regulation
| NCT ID | NCT07082062 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shih Chien Huang |
| Condition | Overweight |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-06-02 |
| Primary Completion | 2025-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-06-02 with a primary completion date of 2025-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial is designed to evaluate the physiological effects of a GLP-1 Formula on glucagon-like peptide-1 (GLP-1) secretion and glycemic regulation in adults with elevated body fat percentage. The GLP-1 Formula is a multi-component dietary supplement composed of Bifidobacterium breve (probiotic), ClpB Formula-a prebiotic blend containing probiotic kombucha extract, soy peptide powder, L-arabinose, and erythritol-and rocket apple extract. The study consists of two randomized crossover trials: Trial 1 (n = 50) aims to assess the effects of the formula on circulating GLP-1 concentrations, while Trial 2 (n = 50) investigates its impact on blood glucose and insulin responses. Eligible participants will be healthy adults aged 18 to 50 years with a body fat percentage greater than 25%, recruited via institutional and online outreach. Participants may choose to enroll in either or both trials; if enrolled in both, a washout period of at least one month between trials is required. Each trial consists of two intervention visits following a crossover design, with supplementation switched on day 8. Each visit will last approximately 6 hours, during which physiological and biochemical assessments will be conducted. Primary outcome measures include plasma levels of GLP-1, glucose, and insulin; secondary outcomes include appetite-related indices. This study aims to elucidate the potential of this functional formula to modulate incretin response and glycemic homeostasis in individuals with elevated adiposity.
Eligibility Criteria
Inclusion Criteria: * Male or female participants aged 18-50 years with a body fat percentage greater than 25%. Exclusion Criteria: * Use of probiotics, weight loss products, or gastrointestinal health-related supplements or medications within the past month. * Presence of diabetes, autoimmune diseases, cancer, chronic gastrointestinal disorders, lactose intolerance, or chronic diarrhea. * History of gastrointestinal surgery. * Pregnant or breastfeeding women.
Contact & Investigator
Shih-Chien Huang, PhD, Associate Professor
PRINCIPAL INVESTIGATOR
Chung Shan Medical University
Frequently Asked Questions
Who can join the NCT07082062 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07082062 currently recruiting?
Yes, NCT07082062 is actively recruiting participants. Contact the research team at schuang@csmu.edu.tw for enrollment information.
Where is the NCT07082062 trial being conducted?
This trial is being conducted at Taichung, Taiwan.
Who is sponsoring the NCT07082062 clinical trial?
NCT07082062 is sponsored by Shih Chien Huang. The principal investigator is Shih-Chien Huang, PhD, Associate Professor at Chung Shan Medical University. The trial plans to enroll 100 participants.